Efficacy and Safety of Liver Transplantation for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: a Single-arm, Multicenter, Prospective Study (HCC-BDTT in LT)

Launched by ZHEJIANG UNIVERSITY · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of liver transplantation (LT) for patients with a specific type of liver cancer called hepatocellular carcinoma (HCC) that has spread into the bile ducts, known as bile duct tumor thrombus (BDTT). Currently, there are no clear treatment guidelines for this condition, which makes it very challenging to treat. The trial aims to find out if liver transplantation can improve survival rates and quality of life for these patients. Over four years, researchers will enroll patients who are confirmed to have HCC with BDTT and follow their progress to see how well they do after the surgery.

To be eligible for this trial, participants must be between 18 and 70 years old, have a confirmed diagnosis of HCC with BDTT, and be healthy enough to undergo surgery. They also need to give their written consent to participate. The study is not yet recruiting participants, but once it starts, those who join can expect close monitoring during their treatment and follow-up care to assess their recovery and overall health. This research could help improve future treatment guidelines and provide valuable insights into managing this complex condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) age between 18 and 70 years; (2) Postoperative pathological diagnosis of HCC with BDTT requiring LT; (3) the general condition can tolerate the operation; (4) written informed consent given by the patient; (5) patients without distant metastasis.
• Exclusion Criteria:
• • (1) Those who did not undergo regular LT for various reasons, split LT, reduced-size LT, simultaneous transplantation, re-transplantation, multiple-organ recipients are excluded; (2) Additional surgical procedures such as pancreaticoduodenectomy were performed; (3) those with other diseases such as active pulmonary tuberculosis, coronary heart disease, renal insufficiency and so on, which affect the therapeutic effect; (4) Extensive abdominal metastasis was found during operation; (5) serious consequences or deaths caused by anesthesia accident during operation; (6) Postoperative death due to other diseases such as traffic accidents, cardiovascular and cerebrovascular accidents; (7) With distant metastasis before operation.